CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on the commercial potential of MTH1 inhibitors, which were identified as critical for cancer cell survival. The inhibitors selectively target cancer cells while minimizing toxicity to normal cells, offering a novel cancer treatment approach.
In our ERC grant GEnetic NEtworks as a tool for anti-CAncer Drug Development we used phenotypic screening and genetic networks to identify the DNA repair protein MTH1 as a critical component for cancer cell survival and we developed selective sub nM inhibitors to MTH1, which specifically kill cancer cells and tumours, whilst being less toxic to primary cells.
Our approach provides a novel concept for treating cancer.
Here, we want to explore the commercial potential of the MTH1 inhibitors identi…
KAROLINSKA INSTITUTET
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
KAROLINSKA INSTITUTET INNOVATIONS AB
Sweden, Solna
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
